RTOG 0920 protocol — A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

NRG Oncology's page for RTOG 0920, a phase 3 trial of post-operative IMRT with or without cetuximab for intermediate-risk resected head and neck cancer. The protocol prescribes 60 Gy in 2 Gy fractions (optional 66 Gy high-risk and 56 Gy at-risk levels) and lists IMRT planning goals for the cord and brainstem planning risk volumes, lips, oral cavity, parotids, pharynx, cervical esophagus, larynx and mandible, with a planning priority order. DoseLab read section 6.5.4 of the version dated 25 January 2016 (copy hosted by the University of Cincinnati) for the oral cavity, lip and cervical esophagus values in the head and neck table.

A widely used US source of head and neck IMRT organ goals; the origin of the oral cavity, lip and cervical esophagus values in DoseLab's head and neck table.